Skeletal Muscle-Derived Cell Implantation for the Treatment of Fecal Incontinence: A Randomized, Placebo-Controlled...

Area of Science:

• Regenerative Medicine
• Gastroenterology
• Pelvic Floor Disorders

Background:

• Fecal incontinence (FI) is a debilitating condition with limited effective treatments.
• Autologous skeletal muscle-derived cell injections have shown potential for improving FI.
• A multicenter, placebo-controlled study was needed to validate efficacy and safety.

Purpose of the Study:

• To evaluate the efficacy and safety of autologous skeletal muscle-derived cell therapy for fecal incontinence.
• To determine the optimal cell dosage for treatment.
• To identify patient subgroups most likely to benefit from this therapy.

Main Methods:

• A randomized, placebo-controlled trial involving patients with at least 6 months of FI.
• Patients received either cell-free medium or low/high doses of cells, alongside pelvic floor electrical stimulation.
• Outcomes assessed included incontinence episode frequency, quality of life, and anorectal function for up to 12 months.

Main Results:

• Cell therapy significantly improved incontinence episode frequency compared to placebo.
• Patients with limited FI duration and high baseline incontinence episode frequency showed the greatest response.
• Higher cell doses demonstrated sustained or increased benefits, while lower doses and placebo showed diminished effects over time. No significant adverse events were reported.

Conclusions:

• High-dose autologous skeletal muscle-derived cell therapy, combined with electrical stimulation, offers a significant improvement in fecal incontinence.
• This approach is particularly effective in patients with shorter FI duration and high baseline incontinence episode frequency.
• Further phase 3 trials are warranted to confirm these findings and establish cell therapy as a viable treatment option for FI.